oligonucleotidebas
therapeut
hail
next
great
wave
biotechnolog
revolut
start
antisens
oligonucleotid
aso
nearli
year
ago
rna
interfer
rnai
current
rnai
latest
research
tool
real
potenti
therapeut
drug
modal
research
tool
evid
rnai
revolution
biolog
scienc
allow
select
silenc
messeng
rna
mrna
express
advent
postgenom
era
rnai
offer
therapeut
platform
identifi
potenti
picomolar
activ
drug
candid
target
includ
convent
undrugg
review
discuss
progress
made
develop
rnai
therapeut
treatment
respiratori
diseas
address
avail
onlin
wwwsciencedirectcom
sirna
lung
research
tool
therapeut
drug
oligonucleotidebas
therapeut
hail
next
great
wave
biotechnolog
revolut
start
antisens
oligonucleotid
aso
nearli
year
ago
rna
interfer
rnai
current
rnai
latest
research
tool
real
potenti
therapeut
drug
modal
research
tool
evid
rnai
revolution
biolog
scienc
allow
select
silenc
messeng
rna
mrna
express
advent
postgenom
era
rnai
offer
therapeut
platform
identifi
potenti
picomolar
activ
drug
candid
target
includ
convent
undrugg
review
discuss
progress
made
develop
rnai
therapeut
treatment
respiratori
diseas
rna
interfer
rnai
repres
natur
endogen
mechan
cell
util
regul
rna
express
review
see
possibl
har
pathway
multipl
mean
includ
microrna
mirna
vectorbas
short
hairpin
rna
shrna
synthet
small
interf
rna
sirna
gene
silenc
induc
sirna
sequencespecif
cleavag
perfectli
complementari
messeng
rna
mrna
wherea
mirna
mediat
translat
repress
transcript
degrad
imperfectli
complementari
target
figur
abil
sirna
potent
revers
silenc
gene
vivo
make
particularli
well
suit
therapeut
addit
enter
rnai
pathway
later
sirna
less
like
interfer
gene
regul
endogen
mirna
synthet
sirna
also
potenti
advantag
druglik
properti
sirna
often
improv
introduct
chemic
modif
manufactur
process
usual
amen
scaledup
product
result
sirna
class
rnai
therapeut
advanc
preclin
clinic
studi
identif
potenti
potent
lead
sirna
candid
usual
begin
bioinformat
design
sirna
synthesi
follow
vitro
character
sirna
activ
specif
ultim
result
select
sirna
drug
candid
usual
subnanomolar
picomolar
activ
figur
identifi
potenti
optim
sirna
druglik
properti
major
hurdl
effect
deliveri
target
cell
remain
typic
involv
investig
vivo
efficaci
safeti
along
addit
studi
examin
pharmacokinet
biodistribut
cellular
uptak
formul
sirna
figur
multipl
approach
deliveri
sirna
publish
rang
rel
simplic
direct
administr
salineformul
sirna
liposomebas
polymerbas
nanoparticl
approach
sirna
conjug
complex
approach
formul
deliveri
approach
employ
today
silenc
achiev
sever
tissu
cell
type
notabl
direct
deliveri
sirna
central
nervou
system
lung
epitheli
cell
system
deliveri
sirna
hepatocyt
tumor
cell
although
multipl
rout
administr
use
sirna
publish
rang
direct
inject
target
tissu
system
administr
use
sirna
treatment
respiratori
diseas
tend
focu
direct
intratrach
intranas
deliveri
sirna
lung
tabl
addit
sever
differ
formul
investig
deliveri
sirna
lung
report
success
use
simpl
salin
formul
tabl
direct
instil
sirna
lung
offer
sever
import
benefit
deliveri
sirna
directli
lung
advantag
drug
dose
sirna
requir
efficaci
substanti
lower
administ
near
target
cell
type
addit
direct
deliveri
might
also
reduc
theoret
undesir
system
side
effect
lastli
importantli
context
treat
respiratori
diseas
instil
sirna
instanc
intranas
intratrach
administr
allow
direct
access
lung
epitheli
cell
import
cell
type
varieti
pulmonari
disord
among
myriad
lung
patholog
epitheli
cell
thought
play
import
role
diseas
cystic
fibrosi
chronic
obstruct
pulmonari
diseas
asthma
pulmonari
fibrosi
addit
multipl
virus
infect
lung
epithelium
includ
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
influenza
rhinovirus
sever
acut
respiratori
syndrom
sar
corona
viru
scv
consequ
mani
viral
endogen
gene
target
especi
pertain
lung
epitheli
cell
silenc
use
sirna
multipl
airborn
diseas
infect
lung
use
entri
site
system
infect
sirna
rapidli
design
target
causal
agent
viral
infect
viru
surprisingli
sirna
therapeut
design
target
mani
differ
respiratori
virus
includ
rsv
piv
sarsscv
influenza
tabl
import
studi
barik
colleagu
demonstr
mice
singl
intranas
administr
mg
sirna
target
either
rsv
piv
p
protein
essenti
subunit
viral
rna
polymeras
reduc
viral
titer
rsv
piv
three
order
magnitud
administ
infect
either
unformul
form
lipoplex
transittko
moreov
therapeut
applic
rsv
sirna
three
day
postinfect
reduc
viral
titer
two
order
magnitud
diseas
patholog
associ
rsv
infect
also
significantli
allevi
rsv
sirna
treatment
observ
side
effect
importantli
specif
antivir
effect
clearli
demonstr
rsvdirect
pivdirect
sirna
affect
replic
intend
viru
author
also
show
combin
rsvdirect
pivdirect
sirna
could
administ
effect
even
case
viral
coinfect
use
similar
approach
intranas
administ
sirna
target
sar
corona
viru
formul
glucos
substanti
inhibit
viral
replic
improv
lung
patholog
nonhusirna
lung
de
fougerol
novobrantseva
rna
interfer
mammalian
cell
rna
interfer
rnai
pathway
involv
either
small
interf
rna
sirna
microrna
mirna
sirna
pathway
involv
cleavag
long
doublestrand
rna
dsrna
dicer
enzym
complex
yield
sirna
sirna
load
argonaut
rnaiinduc
silenc
complex
risc
load
rna
duplex
perfect
sequenc
complementar
cleav
passeng
sens
strand
activ
risc
contain
guid
antisens
strand
produc
activ
risc
guid
strand
recogn
target
site
mrna
perform
sitespecif
cleavag
mrna
rnai
therapeut
develop
har
sirna
pathway
usual
involv
deliveri
synthet
sirna
cell
cytoplasm
contrast
mirna
pathway
begin
endogen
encod
primari
microrna
transcript
primirna
transcrib
polymeras
ii
pol
ii
process
drosha
enzym
complex
form
precursor
microrna
premirna
export
cell
cytoplasm
exportin
precursor
mirna
bound
cytoplasm
dicer
complex
process
load
complex
rna
duplex
load
risc
imperfect
sequenc
complementar
passeng
sens
strand
unwound
leav
matur
mirna
bound
activ
risc
mirna
recogn
target
site
usual
utr
mrna
lead
translat
repress
bind
mirna
target
mrna
may
also
lead
certain
case
mrna
degrad
process
p
bodi
modifi
permiss
natur
review
drug
discoveri
man
primat
model
viral
infect
summari
result
underscor
abil
direct
lung
instil
salineformul
virusspecif
sirna
impact
viral
replic
improv
diseas
patholog
speci
rang
rodent
nonhuman
primat
anoth
viru
publish
suscept
sirnamedi
inhibit
influenza
two
separ
relat
studi
shown
sirna
molecul
direct
nucleoprotein
np
acid
polymeras
pa
influenza
gene
could
protect
mice
lethal
influenza
infect
includ
viru
one
studi
polyethylenimin
pei
complex
sirna
inject
intraven
shown
reduc
viral
titer
peicomplex
sirna
reduc
viral
load
even
administ
postinfect
second
studi
hydrodynam
inject
sirna
follow
intranas
administr
oligofectaminesirna
complex
reduc
viral
titer
least
confer
surviv
lethal
respiratori
figur
develop
rnai
therapeut
sever
step
typic
requir
identif
rnai
therapeut
select
lead
sirna
candid
usual
begin
bioinformat
design
extend
empir
test
potenti
sirna
lead
candid
varieti
vitro
assay
appropri
select
immunostimulatori
profil
lead
optim
proce
introduct
stabil
chemic
modif
requir
along
addit
vitro
test
select
potenc
final
step
involv
identif
effect
safe
deliveri
formul
multipl
deliveri
strategi
exist
includ
sirna
conjug
sirna
encapsul
nanoparticl
liposom
beyond
assess
efficaci
safeti
vivo
paramet
pharmacokinet
biodistribut
cellular
uptak
also
usual
investig
success
typic
lead
research
develop
activ
includ
formul
optim
manufactur
analyt
method
develop
comprehens
safetypharmacolog
analys
multipl
speci
tabl
vivo
efficaci
use
sirna
pulmonari
model
report
posit
vivo
efficaci
lung
list
along
formul
rout
administr
anim
model
util
anim
model
conduct
mous
except
sar
infect
studi
perform
nonhuman
primat
dextros
np
nanoparticl
pei
polyethylenimin
rsv
respiratori
syncyti
viru
piv
parainfluenza
viru
sar
sever
acut
respiratori
distress
syndrom
gfp
green
fluoresc
protein
infect
mice
limit
attempt
detect
nonspecif
activ
immun
system
sirna
report
neg
given
potent
immunostimulatori
properti
flu
sirna
util
studi
rel
lack
thereof
control
gfp
sirna
use
protect
seen
flu
infect
model
may
mediat
larg
part
sirna
stimul
innat
immun
abil
certain
unmodifi
sirna
elicit
product
proinflammatori
mediat
includ
tnfa
interferon
highlight
care
must
taken
examin
vivo
endpoint
sensit
releas
cytokin
fortun
sever
studi
shown
introduct
base
modif
abolish
doublestrand
rnainduc
cytokin
product
addit
target
viral
genom
success
sirnamedi
silenc
multipl
endogen
lung
target
report
mani
endogen
lung
target
silenc
context
acut
lung
injuri
ali
model
tabl
mous
experiment
ischemiareperfus
injuri
model
intranas
administr
salineformul
heme
oxygenas
specif
sirnaattenu
diseas
although
ischemiareperfusioninduc
express
multipl
organ
includ
epitheli
cell
lung
intranas
administ
sirna
silenc
gene
express
lung
anoth
studi
hyperoxiainduc
lung
injuri
mice
notabl
amelior
intranas
administr
salineformul
chemic
modifi
angiopoietin
sirna
injuri
well
consequenti
inflamm
mortal
cell
death
vascular
permeabl
dramat
reduc
level
equival
seen
angiopoietin
mice
lastli
sever
studi
util
hemorrhageinduc
septic
challeng
model
ali
demonstr
intratrach
administr
salineformul
sirnatarget
keratinocytederiv
chemokin
macrophag
inflammatori
protein
fa
result
target
mrna
silenc
lung
amelior
diseas
patholog
summari
report
suggest
certain
condit
direct
administr
salineformul
sirna
abl
specif
silenc
viral
endogen
gene
target
express
lung
epitheli
cell
studi
requir
fulli
understand
mechan
sirna
uptak
lung
contribut
lung
injuri
sirna
uptak
natur
epitheli
cell
target
whether
lung
cell
type
might
also
target
despit
success
deliv
salinebas
sirna
formul
directli
lung
rodent
nonhuman
primat
improv
desir
formul
could
design
improv
cellular
uptak
cytoplasm
local
sirna
broaden
cell
type
sirna
deliv
improv
pharmacokinet
lung
distribut
profil
sirna
larg
bodi
literatur
experi
gene
therapi
lung
support
feasibl
approach
airwaydirect
oligonucleotid
deliveri
simpl
lung
evolv
physic
immunolog
barrier
hinder
effect
deliveri
formul
review
see
date
sever
differ
formul
test
context
direct
lung
instil
sirna
mix
result
tabl
cation
lipid
genzym
lipid
gl
wellestablish
vehicl
vivo
lung
gene
transfer
util
human
clinic
trial
griesenbach
et
al
assess
vivo
effici
uptak
sirna
airway
epithelium
mice
intranas
deliv
sirna
local
mostli
alveolar
macrophag
function
silenc
airway
epitheli
cell
margin
sirna
specif
betagalactosidas
reduc
mrna
level
airway
epithelium
transgen
mice
onethird
decreas
protein
level
detect
anoth
establish
approach
direct
lung
deliveri
nucleic
acid
involv
chitosan
nanoparticl
chitosan
welltoler
natur
biodegrad
polym
form
cation
complex
nucleic
acid
chitosansirna
duplex
rang
size
nm
shown
reduc
egfp
express
bronchiol
epitheli
cell
transgen
mice
intranas
administr
chitosanegfp
sirna
formul
chitosanbas
nanoparticl
also
use
directli
deliv
shrna
target
rsv
gene
result
signific
antivir
activ
recent
work
identifi
degre
deacetyl
higher
chitosan
molecular
weight
import
paramet
effici
sirnamedi
knockdown
formul
optim
probabl
requir
chitosan
consid
robust
formul
sirna
lung
deliveri
third
approach
involv
use
cation
cell
penetr
peptid
cpp
tat
mediat
sirna
deliveri
across
cellular
membran
unfortun
despit
previou
studi
show
efficaci
sirnacpp
vitro
conjug
sirna
tat
penetratin
fail
result
sirnamedi
knockdown
mapk
mrna
mous
lung
vivo
lastli
influenza
viru
envelop
virosom
publish
deliv
sirna
lung
use
virosom
especi
benefici
antivir
sirna
deliveri
lung
virosom
expect
taken
cell
infect
viru
howev
progress
virosom
research
hamper
difficulti
manufactur
viral
envelop
although
effort
new
sirna
formul
focus
improv
direct
lung
deliveri
sever
approach
use
system
administr
target
sirna
lung
cation
liposom
util
deliv
sirna
lead
reduct
mous
lung
endothelia
result
expect
physiolog
effect
lastli
live
et
al
recent
demonstr
peicomplex
sirnadirect
reduc
airway
resist
allergeninduc
airway
hypersensit
mous
model
deliv
intraven
date
half
dozen
human
clinic
trial
ongo
use
rnai
includ
one
treatment
rsv
infect
sirna
target
viral
nucleocapsid
n
gene
complet
phase
intranas
inhal
studi
healthi
adult
found
gener
well
toler
alnylam
pharmaceut
cambridg
press
releas
evalu
phase
ii
intranas
adult
experiment
infect
studi
toplin
result
report
show
safe
well
toler
demonstr
statist
signific
antivir
activ
alnylam
pharmaceut
press
releas
develop
sirna
therapeut
sever
major
challeng
remain
overcom
deliveri
paramount
although
success
achiev
direct
instil
salineformul
sirna
progress
requir
formul
need
improv
cellular
uptak
cytoplasm
local
sirna
broaden
lung
cell
type
sirna
deliv
improv
pharmacokinet
lung
distribut
profil
sirna
rapid
preclin
progress
encourag
initi
clinic
result
suggest
sirna
therapeut
may
use
role
treatment
respiratori
diseas
ultim
verdict
util
rnai
broad
therapeut
drug
class
remain
render
rest
human
clinic
trial
data
